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Among vertebrate models, the zebrafish provides a unique 
combination  of  advantages  for  the  study  of  develop­
mental biology, genetics, and genomics, and has proven 
to  be  a  versatile  model  for  studying  disease  (Table  1). 
With blood circulation beginning in externally fertilized, 
transparent embryos within 23­26 hours of fertilization, 
the zebrafish has been particularly useful in the analysis 
of hematopoietic development [1]. In addition, the zebra­
fish  reproduces  rapidly  ­  a  single  pair  can  produce 
hundreds of embryos per week and mass mating strategies 
can produce tens of thousands of synchronized offspring. 
This unique combination provides the scale, visualization, 
and manipulation capabilities required for novel genome­
wide  studies  of  hematopoiesis  and  blood  diseases  in  a 
vertebrate model. To this end, mutagenesis and suppres­
sor screens have been used to find interesting phenotypes 
associated with defective hematopoiesis [2,3]. Chemical 
genetics studies have investigated a variety of pathways, 
and  large­scale  chemical  screens  have  identified  many 
small  molecules  displaying  clinical  promise  [4­6].  The 
zebrafish provides a comparable genome to other verte­
brate species and has been used in studies analyzing gene 
expression and epigenetics [7,8]. Furthermore, the use of 
morpholino  oligonucleotides  to  examine  gene  knock­
downs in a whole vertebrate has allowed the zebrafish to 
be  more  widely  used  [9].  As  a  result  of  these  charac­
teristics, the zebrafish has become an important animal 
model  and  has  provided  new  insights  into  biological 
systems.
Here,  we  highlight  the  advantages  of  the  zebrafish 
model through discussion of promising findings in the 
hematopoietic  field  with  an  emphasis  on  disease 
definition  and  management.  In  particular,  we  evaluate 
mutagenesis,  gene  knockdown,  and  screening  in  the 
zebrafish. These techniques have led to the discovery of 
several  molecules  and  gene  targets  with  therapeutic 
potential, including Tif1gamma, dimethyl prostaglandin 
E2  (dmPGE2),  3F8,  and  thiazole­carboxamide  10A. 
Further  more,  we  highlight  recent  advances  in  the 
understanding  of  blood  diseases,  such  as  T­cell  acute 
lympho  blastic  leukemia  (T­ALL)  and  hypochromic 
anemia.
Abstract
The zebrafish model is rapidly gaining prominence 
in the study of development, hematopoiesis, and 
disease. The zebrafish provides distinct advantages 
over other vertebrate models during early embryonic 
development by producing transparent, externally 
fertilized embryos. Embryonic zebrafish are easily 
visualized and manipulated through microinjection, 
chemical treatment, and mutagenesis. These 
procedures have contributed to large-scale 
chemical, suppressor, and genetic screens to 
identify hematopoietic gene mutations. Genomic 
conservation and local synteny between the human 
and zebrafish genomes make genome-scale and 
epigenetic analysis of these mutations (by microarray, 
chromatin immunoprecipitation sequencing, and 
RNA sequencing procedures) powerful methods 
for translational research and medical discovery. 
In addition, large-scale screening techniques have 
resulted in the identification of several small molecules 
capable of rescuing hematopoietic defects and 
inhibiting disease. Here, we discuss the contributions 
of the zebrafish model to the understanding of 
hematopoiesis, hematopoietic stem cell development, 
and disease-related discovery. We also highlight the 
recent discovery of small molecules with clinical 
promise, such as dimethyl prostaglandin E2, 3F8, and 
thiazole-carboxamide 10A.
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Genome comparison
The  zebrafish  shows  genetic  similarity  to  other  verte­
brates.  At  approximately  1.8  billion  base  pairs,  the 
zebrafish  genome  is  about  two­thirds  the  size  of  the 
human genome [10]. Although the fish genome is vastly 
rearranged, several areas of local synteny and some larger 
chromosomal regions are preserved [11]. This has greatly 
facilitated  positional  cloning  projects,  as  chromosomal 
synteny  can  be  used  as  a  guide  within  the  genome. 
Comparisons  of  chromosomal  arrangements  and  indi­
vidual  DNA  sequences  in  the  zebrafish  have  revealed 
general conservation, particularly for the Hox loci [12]. 
However,  the  zebrafish  genome  incurred  a  significant 
duplication that arose in teleosts about 300 million years 
ago. Because of the early incidence of this duplication in 
teleost evolution, the zebrafish genome has since under­
gone  further  alterations  as  subsequent  deletions  are 
believed to have removed many of the originally dupli­
cated genes [11]. These genomic events are demonstrated 
by the presence of seven Hox clusters in zebrafish com­
pared with only four in humans [12].
These alterations have provided unique opportunities 
for discovery, as they have sometimes led to a splitting of 
regulatory elements. For instance, the zebrafish has two 
independent transferrin receptor­1 genes [13]. One is a 
general, ubiquitously expressed gene and the other is a 
red­blood­cell­specific gene. In humans, there is a single 
gene  for  transferrin  receptor­1  that  is  expressed  both 
highly in red blood cells and ubiquitously at a low level. 
Nevertheless, an independent zebrafish mutant in trans­
ferrin receptor­1 has been isolated that lacks red blood 
cells.  Comparative  genomic  analysis  and  study  of  the 
regulatory sequences in this mutant may prove useful.
Recent technological advances have also made zebra­
fish epigenetic analysis possible, as demonstrated by the 
use  of  chromatin  immunoprecipitation  sequencing 
(ChIP­seq) by a number of laboratories studying specific 
chromatin  or  transcription  factor  binding  in  whole 
zebrafish  embryos  [14,15].  Furthermore,  chromatin  re­
modeling  has  been  evaluated  by  analyzing  specific 
histone modifications, such as methylation and acetyla­
tion. Recent studies have highlighted the specific post­
translational modifications H3K4me3, H3K9ac, and H4ac 
as  activating;  H3K27me3  and  H3K9me3  as  repressing; 
and  H3K36me3  as  being  involved  in  transcriptional 
elongation [16,17]. Through these techniques, the zebra­
fish model has helped to clarify the relationship between 
epigenetics and gene function, and can be expected to 
further contribute to this understanding in the future.
Mutagenesis
The  zebrafish  model  has  been  pioneered  as  a  genetic 
system for studying a variety of different diseases, includ­
ing hematopoietic disorders. In 1996, new mutagenesis 
protocols  allowed  the  derivation  of  many  novel  blood 
mutants  [18,19].  Male  zebrafish  were  soaked  in  ethyl­
nitrosourea (ENU), introducing mutations to the sperm 
or  spermatogonia.  The  males  were  then  mated  with 
females, creating progeny that carried over 100 mutations 
per  genome.  Outcrossing  these  mutants  formed  F2 
families, which were subsequently crossed to analyze the 
autosomal  recessive  or  dominant  hematopoietic  muta­
tions in the F3 generation. The initial experiment derived 
more than 50 independent blood mutants that formed 26 
complementation  groups  when  cross­mated  [18,19]. 
Most of the mutated genes have since been isolated and 
linked to many defects in mesoderm induction, stem, or 
progenitor  cell  formation,  and  erythroid  or  T­cell 
develop  ment  [20].  Analysis  of  several  red  blood  cell 
mutants isolated novel genes that correlated to mutations 
found in several human subjects with anemia. At least 
three independent zebrafish mutations, and the resulting 
blood disorders, have contributed to the discovery of the 
molecular basis of human diseases (Table 2) [21­23].
Other large­scale approaches have been applied to the 
zebrafish  system.  One  uses  ‘targeting­induced  local 
lesions  in  genomes’  (TILLING),  a  process  by  which 
Table 1. Advantages of the zebrafish model
Zebrafish trait/procedure  Advantages provided
Externally fertilized, transparent embryos  Visualization (fluorescence or morphologic screening); manipulation (morpholino, DNA, RNA injection)
Blood circulation by 23-26 hpf  Rapid initiation of hematopoiesis
Sexual maturity at 3 months  Short generation time for increased genetic manipulation and transgenic development
Large clutch size (100-200 embryos per pair   Increased likelihood of success for low probability genetic crosses/transgenic development; massive clutches of 
or 10,000+ embryos per mass mating)  synchronized embryos make large-scale screening protocols possible
Conserved hematopoietic system  Relevant model for comparison with human/mammalian systems
Fluorescent and confocal microscopy   Increased visual resolution resulting in greater potential for hematopoietic fate mapping 
procedures
Transplantable kidney marrow  Ability to perform competitive transplantation assays screening for molecules capable of enhancing HSC  
  development and engraftment and hematopoiesis 
hpf, hours post-fertilization; HSC, hematopoietic stem cell.
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carried out to identify mutations within a particular gene, 
essentially  mimicking  the  outcome  of  targeted  muta­
genesis [24]. This approach has led to the derivation of 
mutants  in  the  runx1  and  gata1  genes,  which  encode 
transcription  factors  specific  to  the  blood  program 
[25,26]. Furthermore, an insertional mutagenesis screen 
was  conducted  by  Nancy  Hopkins  and  co­workers,  in 
which  a  retrovirus  was  inserted  into  the  genome  to 
promote  random  mutagenesis  [27,28].  The  recovered 
mutations  defined  315  independent  mutants  affecting 
early development. In another study, retroviral insertions 
were  shown  to  be  highly  efficient  on  a  genome­wide 
scale,  with  nearly  one  in  five  integrations  resulting  in 
mutation  [29]. The  mutants  discovered  in  these  large­
scale screens have proved extremely useful, with some 
associated with cancer phenotypes and others affecting 
individual organs.
In the zebrafish system, haploid genetics can also be 
used [30­32]. This is extremely powerful as it reduces the 
extensive requirements typically associated with genetic 
screens. In a haploid screen, males are mutagenized (with 
ENU) and mated with a female. The eggs produced by the 
second­generation  females  are  studied  by  in  vitro 
fertilization with UV­irradiated sperm. The UV irradia­
tion  functionally  inactivates  the  paternal  DNA  while 
maintaining  sperm  fertility,  thus  creating  haploid 
animals. Zebrafish haploids typically survive for 4 days, 
but the reason for death is unclear. However, given that 
blood  formation  occurs  within  the  first  36  hours  of 
development,  haploid  screens  can  be  used  to  study 
independent hematopoietic mutants. A recent variant of 
such  a  screen  used  early  pressure  to  identify  several 
mutants  that  affected  T­cell  development  [20,33].  The 
early  pressure  method  suppresses  the  second  meiotic 
division, generates gynogenetic diploids, and thus elimi­
nates the additional complexity created by heterozygosity 
[34]. Using  this  particular  method,  the  sart3  gene  was 
found to be critically required for thymus development 
through regulation of the U6 small nuclear ribonucleo­
protein [35].
Morpholinos and gene knockdown
Morpholinos  are  small  antisense  oligonucleotides  that 
are  constructed  to  specifically  target  sequences  at  the 
transcriptional start site (ATG morpholinos) or at intron­
exon  splice  junctions  (splicing  morpholinos)  and  allow 
selective  inhibition  of  a  target  gene  [34].  The  use  of 
morpholinos  has  greatly  expanded  the  versatility  and 
importance of the zebrafish model in biomedical sciences 
[9,36,37].
Morpholinos  have  been  used  extensively  for  the 
knockdown of a variety of hematopoietic genes and have 
proven to be an important tool for genetic screens. For 
instance, we are currently conducting a chromatin factor 
screen,  targeting  over  480  independent  factors  via 
morpholino knockdown, to determine DNA rearrange­
ment requirements in hematopoiesis. This screen provides 
a means for determining the role of chromatin factors in 
the birth of hematopoietic stem cells (HSCs) in the aorta 
and in globin expression (HT Huang, K Kathrein, and LI 
Zon, unpublished).
A new era of genetic suppressor screens
Recently, we undertook a novel genetic suppressor screen 
in the search for recessive mutants that rescue a zebrafish 
mutant phenotype (Figure 1) [2]. This screen focused on 
the mutant moonshine, which completely lacks blood due 
to  a  defect  in  the  chromatin  factor  Tif1gamma  [38]. 
Tif1gamma  contains  several  motifs,  including  a  PHD 
finger­bromodomain  and  a  ring  finger  domain,  and 
several laboratories have demonstrated its involvement 
in transforming growth factor beta (TGF­beta) signaling 
[39,40]. The aforementioned screen [2] sought another 
gene that, when mutated, would restore blood develop­
ment in moonshine. To this end, moonshine was rescued 
with a transgenic bacterial artificial chromosome (BAC) 
containing the wild­type copy of tif1gamma. The BAC 
Table 2. Using the zebrafish model for gene/protein or small-molecule discovery relevant to human blood disorders 
Zebrafish mutant  Human disorder or     
(protein or small molecule)  potential therapeutic application  Known function   Discovery 
weissherbst* (ferroportin)  Hemochromatosis   Iron export†‡   [21] 
frascati* (frs) (mitoferrin)  Hypochromic anemia   Iron assimilation†‡   [22]
shiraz* (sir) (glutaredoxin 5)  Hypochromic anemia   Assembly of Fe-S cluster†‡   [23]
Dimethyl prostaglandin E2  Bone marrow transplant therapy (clinical trial)  Enhanced HSC engraftment†   [45]
3F8  GSK3 implicated in type II diabetes, bipolar disorder,   Inhibits GSK3†   [47]
  Alzheimer’s disease, some cancers
Thiazole-carboxamide 10A  PLK1 upregulated in many cancers   Inhibits PLK1†   [81]
GSK3, glycogen synthase kinase 3; HSC, hematopoietic stem cell; PLK1, polo-like kinase 1. *Three hematopoietic mutations originally identified in zebrafish have since 
been linked to human genetic mutation and disease (see text for details). †Known function in zebrafish. ‡Known function in humans.
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cent protein (GFP) expression, resulting in stable trans­
genic fish that were both green and homozygous mutant 
at  the  endogenous  tif1gamma  locus.  These  fish  were 
mutagenized and a haploid screen was conducted. Half of 
the  screened  embryos  were  GFP  positive  and  half 
displayed  the  moonshine  phenotype.  A  suppressor  was 
defined as a recessive mutation resulting in the rescue of 
blood in at least half of the mutant phenotypes. Using 
this zebrafish screening model, we discovered two inde­
pendent suppressors (sunshine and eos) [2]. We mapped 
the sunrise suppressor to cdc73, a gene involved in the 
polymerase­associated  factor  (PAF)  complex,  which  is 
required for transcription elongation. The PAF complex 
includes several other factors, which, when inactivated in 
the moonshine background, also resulted in rescue. This 
demonstrated  involvement  of  the  PAF  complex  in 
hematopoietic  cell  transcriptional  elongation.  Purifica­
tion of the complex bound to Tif1gamma demonstrated 
the  transcriptional  involvement  of  other  cell­specific 
regulators, including Gata1 and the basic helix­loop­helix 
transcription factor Scl, and the elongation factor P­Tefb, 
Figure 1. Genetic suppressor screens in zebrafish reveal additional mutations capable of rescue. (a) The bacterial artificial chromosome 
(BAC) transgenic construct containing a wild-type Tif1gamma locus and green fluorescent protein (GFP) driven by an actin promoter (Pactin) used 
in our recent genetic suppressor screen [2]. The transgene was injected into one-cell-stage embryos (right) to rescue the lethality of Tif1gamma 
mutant (mon) fish. (b) Schematic diagram of the suppressor screen. Stable transgenic fish are homozygous mutants for the endogenous tif1gamma 
locus (mon/mon) but retain viability because they are heterozygous for the transgene. The GFP marker on the transgene makes them green 
fluorescent. F0 males were mutagenized with ethylnitrosourea (ENU). In the F1 generation, 25% of progeny were transgene homozygotes (Tg 
homo, mon/mon; Tg/Tg, bright green), 50% were transgene heterozygotes (Tg het, mon/mon; Tg/+, light green, in red circle), and 25% lacked the 
transgene (No Tg, mon/mon, gray). Only the progeny that were heterozygous for the transgene were raised to adults. The F1 females were then 
squeezed to provide unfertilized eggs that were activated by UV-treated sperm. The UV treatment destroys the paternal DNA while still allowing 
fertilization. The resulting F2 embryos were haploid and were subjected to in situ hybridization (ISH) at 22 hours post-fertilization for GFP and beta e3 
globin probes. Transgenic embryos (mon;Tg) were positive for both probes, whereas non-transgenic embryos (mon) were negative for both probes. 
However, embryos that were negative for GFP but positive for globin indicated the presence of a genomic suppressor (sup) mutation. Modified, 
with permission, from [2].
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RNA  polymerase  II  and  its  regulator  DRB  sensitivity­
inducing factor (DSIF) [2]. This suggests a model whereby 
all blood gene transcription in moonshine is paused until 
the  additional  mutation  in  the  PAF  or  DSIF  complex 
promotes  rescue  by  obstructing  transcriptional  inhibi­
tion. This novel mechanism has also been observed in 
other cell types, including in melanocyte cell fate regu­
lation [41].
In  another  suppressor  screen  we  analyzed  the  cdx4 
mutant  kgg,  which  is  defective  in  HSC  development 
because of abnormal hox gene expression [42,43]. Several 
chemicals were found to rescue the cdx4 mutant, many of 
which  are  involved  in  the  retinoic  acid  pathway.  This 
suggests that the Cdx­Hox pathway mediates the retinoic 
acid  response  during  hematopoietic  cell  development. 
Through these types of large­scale screens, the zebrafish 
model provides a means of defining connections between 
abnormal gene function and their respective pathways.
Small-molecule screens in the zebrafish
Zebrafish  embryos  have  become  a  very  useful  tool  for 
studying developmental responses to chemical treatment 
[44]. We recently conducted a chemical screen investi­
gating  the  birth  of  HSCs  in  the  aorta.  In  this  screen, 
individual embryos were placed into a 96­well plate and 
chemically  treated  (Figure  2)  [45].  Embryos  were  then 
stained for the stem cell markers Runx1 and c­Myb. The 
screen revealed 35 chemicals capable of enhancing HSC 
engraftment, the most potent of which was dmPGE2, a 
known  small  lipid  mediator  of  inflammation  that  is 
upregulated  during  marrow  transplantation.  Following 
its  discovery  in  zebrafish,  we  tested  the  efficacy  of 
dmPGE2 in mammals using a limited­dilution competi­
tive  repopulation  assay  in  mouse  marrow  transplants, 
which showed a fourfold increase in HSC engraftment. 
This increase is sufficient for therapeutic consideration. 
For instance, current cord blood transplantation uses a 
single  cord  for  young  children,  whereas  adult  trans­
plantation requires two cords. dmPGE2 increases cord 
blood  engraftment  in  non­obese  diabetic  severe  com­
bined immunodeficiency (NOD/SCID) animals and has 
been  shown  to  be  non­toxic  in  primate  competitive 
trans  plant models [46].
Many  other  small­molecule  screens  have  been  per­
formed, contributing equally promising candidate chemical 
treatments.  The  discovery  of  3F8,  a  novel  inhibitor  of 
glycogen synthase kinase 3 (Gsk3), has great potential as 
a candidate for therapeutic use. Gsk3 is a key member of 
the Wnt and hedgehog signaling pathways and has been 
linked to a number of human diseases, including type 2 
diabetes, bipolar disorder, Alzheimer’s disease, and some 
cancers [47]. The combination of multiple pathway involve­
ment  and  multiple  disease  implication  makes  Gsk3  a 
potentially important drug target. In a recent chemical 
screen of 4,000 compounds, 3F8 was found to phenocopy 
the ‘no­eyes’ embryonic zebrafish phenotype observed in 
cases  of  Wnt  overexpression,  as  the  result  of  Gsk3 
inhibition [48]. Subsequent analysis has shown 3F8 to be 
more selective and potent than the previously used GSK3 
inhibitors,  suggesting  increased  potential  for  research 
and clinical application [48].
These studies demonstrate the advantages provided by 
the zebrafish model as a platform for conducting large­
scale screens for potential molecules that target stem cell 
development, hematopoietic differentiation, and disease­
related mechanisms. Small­molecule screens have proven 
invaluable to the discovery and evaluation of chemicals 
displaying potential for clinical research and as reagents 
for translational research.
Hematopoiesis in the zebrafish and mammals
Zebrafish  hematopoietic  development  occurs  in  two 
waves, an embryonic and a definitive wave, and seems to 
be highly conserved in mammals (Figure 3) [49,50]. The 
zebrafish embryonic wave initiates at the 1­3 somite stage 
when  hemangioblasts  develop.  This  process  is  com­
parable  to  mammalian  primitive  hematopoiesis,  which 
takes  place  in  the  yolk  sac  mesodermal  cells  [51].  The 
cells arising from these tissues are the early progenitors 
of  endothelial  and  hematopoietic  cells.  The  further 
differentiation of these tissues occurs early in develop­
ment (about 15 hours post­fertilization (hpf)) in zebrafish 
and  about  19  days  post­fertilization  (dpf)  in  humans) 
[51]. In zebrafish, this differentiation is characterized by 
two stripes of lateral mesoderm that converge toward the 
midline before fusing to form the blood island [51]. The 
blood island serves as the functional equivalent of the 
mammalian  yolk  sac  and  is  the  developmental  site  of 
primitive  erythrocytes  and  some  myeloid  components 
[52]. At 36 hpf, HSCs are formed in the ventral wall of the 
dorsal aorta in a similar manner to that seen in other 
vertebrates,  a  process  that  occurs  at  day  27  in  human 
development  [49].  This  HSC  formation,  in  the  aorta 
gonad  mesonephros  (AGM)  region  of  each  organism, 
marks the beginning of the definitive wave of hemato­
poiesis,  with  the  majority  of  these  cells  functioning  as 
progenitors  and  a  few  others  acquiring  self­renewal 
ability.  The  zebrafish  definitive  wave  continues  in  the 
caudal hematopoietic tissue (CHT; about 3 dpf) before 
seeding the kidney (about 4 dpf), whereas in humans the 
definitive wave continues in the fetal liver and placenta 
(about 35 dpf) before seeding the spleen, thymus, and 
bone marrow [53,54]. The ability to study primitive and 
definitive hematopoiesis in an externally fertilized, and 
thus  more  accessible,  vertebrate  species  has  facilitated 
the  dissection  of  several  signaling  pathways  regulating 
hematopoiesis.
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The ontogeny of HSCs has been a major focus of research 
in the blood research community. Use of the cd41­GFP 
zebrafish transgenic line has shown that HSCs are first 
derived  in  the  AGM  region  and  are  marked  by  CD41 
positivity  [55,56].  Further  analysis  using  the  cd41­GFP 
line has led to the observation that CD41­positive cells 
exist in two distinct populations, which are manifested as 
GFP(hi) or GFP(lo) cells in this system [56]. After sorting by 
flow cytometry, each CD41 population was evaluated for 
long­term  engraftment  and  multilineage  reconstitution 
in  sublethally  irradiated  zebrafish.  The  resulting  data 
indicate that cd41­GFP(lo) cells represent true HSCs, as 
these  cells  are  capable  of  both  engraftment  and  long­
term sustainment of the hematopoietic program [56].
The origin of HSCs has long been an important topic in 
the  hematopoietic  field.  However,  recent  advances  in 
zebrafish  live  imaging  technology  have  provided  new 
insights  into  HSC  emergence  from  the  AGM  region. 
Transgenic  zebrafish  with  red­labeled  endothelial  cells 
and green­labeled blood cells have been used to directly 
visualize the budding process of HSCs from aorta endo­
thelial cells [57­59]. Using the kdr­GFP transgenic zebra­
fish line, which drives GFP expression under the control 
of  the  kdrl  gene  promoter  in  vasculature  starting  at 
18  hpf,  time­lapse  fluorescence  confocal  microscopy 
revealed endothelial cells emerging from the aortic floor 
and entering the sub­aortic space starting at 30 hpf, a 
process that has been termed endothelial hematopoietic 
transition (EHT) [59]. The emergent kdr­GFP+ cells are 
morphologically consistent with hematopoietic progenitor 
cells and are shown to seed the CHT (35 hpf) and thymus 
(3 dpf). runx1 morpholino knockdown in the kdr­GFP 
line  has  also  demonstrated  that  the  EHT  event  is  a 
Runx1­dependent process, as the budding process does 
not occur in the absence of Runx1 [58,59].
Figure 2. Large-scale vertebrate chemical screening made possible by zebrafish. Embryos are incubated in groups of 5-10 with approximately 
2,500 different chemicals. At 36 hours post-fertilization, in situ hybridization is conducted to analyze the expression of early hematopoietic markers 
such as runx1 and c-myb. The embryos are then scored for a change in hematopoietic expression. We recently used this technique [45] to identify 
82 compounds that influence hematopoietic stem cell differentiation, the most prominent of which was dimethyl prostaglandin E2 (dmPGE2). 
Modified with permission, from [45].
X
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for runx1 and  cmyb
Incubate embryos with chemicals
n = 2498
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difficult until the recent development of an adult trans­
plant zebrafish model called Casper [60]. The Casper line 
lacks pigmentation, which allows individual cell visualiza­
tion in transplants of fluorescent marrow. This provides 
an adult fate mapping and imaging model that can be 
used to analyze kidney colonization and development.
Fate mapping in the zebrafish
One of the greatest attributes of the zebrafish model is 
the  ability  to  trace  hematopoietic  cell  fate  as  differen­
tiation  occurs  in  the  embryo.  Caged  fluorescein  dye, 
which changes color in response to a laser pulse, can be 
injected into embryos [61­63]. Laser activation of single 
cells, or groups of cells, allows the tracking of individual 
cell  derivation  over  time.  This  technique  has  been 
particularly  useful  in  the  study  of  HSC  development 
within the aorta. ‘Uncaged’ HSCs were followed as they 
colonized the CHT. The cells arising from the CHT then 
seeded the thymus and the kidney [64]. In zebrafish, the 
kidney  serves  as  the  primary  site  of  larval  and  adult 
hematopoiesis  [50].  Analysis  of  fluorescently  labeled, 
mutant, or morphant (morpholino knockdown) cells has 
enabled the investigation of cell migration and develop­
ment.  This  has  led  to  the  discovery  of  chemokine 
receptors that are responsible for thymus colonization in 
the  zebrafish  [65].  In  addition,  fate  mapping  can  now 
make use of transgenic zebrafish containing a Cre­Ert2 
(mutated estrogen receptor) construct that, when initiated, 
switches the expression of an integrated construct from 
the green label GFP to the red label DsRed in specific 
cells or tissues [66]. The progeny of these switched cells 
maintain DsRed expression and are easily traced through 
development. These studies have enabled visualization of 
the  hematopoietic  system  at  significant  resolution  and 
have  been  extremely  useful  for  defining  the  sites  of 
zebrafish hematopoiesis.
In  the  zebrafish,  blastula  transplantation  provides  a 
model for examining cell autonomy in many cell types, 
including  HSCs  [67].  Mutant  or  morphant  cells  are 
injected  with  a  fluorescent  dye  and  then  transplanted 
into a wild­type embryo or vice versa [68]. The implanted 
cells are tracked using their fluorescence. Transplantation 
of  a  fluorescent  mutant  cell  that  results  in  the  lack  of 
Figure 3. Hematopoiesis in zebrafish and humans, and known zebrafish blood mutants. The stages of hematopoiesis are illustrated, with 
the genes and mutants identified as affecting each stage shown (red, zebrafish blood mutants; blue, genes altered by the mutations) and the 
processes in bold below. Bottom: the sites and times of the events shown in human and zebrafish. AGM, aorta gonad mesonephros; CHT, caudal 
hematopoietic tissue; dpf, days post-fertilization; hpf, hours post-fertilization; HSC, hematopoietic stem cell.
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autonomous manner. More recently, this technique has 
been improved to allow transplantation of blastula cells 
from a myb­GFP donor. This transgenic line contains a 
BAC  expressing  GFP  under  the  control  of  a  myb 
promoter, which marks donor cells as they form HSCs in 
the dorsal aorta [45]. These cells are then injected into a 
recipient  containing  a  red  fluorescent  protein  (RFP) 
construct that labels the vasculature red. The derivation 
of green cells adjacent to the red endothelial cells indi­
cates autonomous effects of stem cell production. These 
techniques allow the tracking of individual cells, which is 
very informative in the study of such a dynamic system.
Blood diseases in zebrafish
The zebrafish model has been used in the discovery of 
many  new  compounds  with  potential  for  clinical  and 
thera  peutic applications (Table 2), including several zebra­
fish cancer models that have been introduced over the 
past few years. These models are generally easy to mani­
pu  late and study while showing high genetic similarity to 
human  cancer  lines  [69].  One  such  model  uses  a 
conditional Cre/lox­regulated system under the control 
of a heat shock promoter that drives rag2 expression in 
developing  T  cells  [70,71].  Several  recent  publications 
have investigated this system in the study of T­ALL and 
cancer  biology.  A  recent  T­ALL  study  found  that  high 
levels  of  the  apoptosis  regulator  Bcl2,  the  G­coupled 
protein  receptor  S1p1,  and  the  cell  adhesion  protein 
Icam1  blocked  tumor  cell  intravasation,  an  important 
initial step in metastasis [72]. In addition, results obtained 
using the zebrafish model have allowed the differences 
between human T­cell lymphoblastic lymphoma (T­LBL) 
and  human  T­ALL  to  be  defined  according  to  their 
cellular and molecular components. Currently, human T­
LBL  and  T­ALL  are  treated  with  the  same  regimens; 
however,  these  data  have  demonstrated  key  molecular 
differences that could allow more targeted treatments in 
the future [72].
The characterization of the ferroportin gene by zebra­
fish gene cloning is a prime example of the relevance of 
the zebrafish model for the discovery of disease­related 
genes  [21]. Ferroportin  was  mutated  in  the  weissherbst 
mutant and, using this model, was found to be the iron 
transporter responsible for delivering maternally derived 
iron from the yolk to the embryo. Human placental cells 
have since been found to express ferroportin [73]. Thus, 
maternal  iron  delivery  to  the  fetus  by  ferroportin  has 
been  evolutionarily  conserved  for  300  million  years. 
Furthermore, anemia of chronic disease has been linked 
to  this  gene  through  the  ligand  hepcidin,  which  binds 
ferroportin and promotes its internalization. Dysregula­
tion  of  this  pathway  can  lead  to  hemochromatosis,  an 
iron imbalance disorder [74]. Ferroportin mutations have 
been  found  in  several  patients  with  hemochromatosis, 
and this illustrates how studies of a zebrafish mutant have 
contributed to the definition of a human disease. More 
recently,  mitoferrin  and  glutaredoxin  5  have  also  been 
linked to iron defects.
Since its discovery as an enhancer of HSC development 
in zebrafish, dmPGE2 is advancing towards clinical use. 
A  clinical  trial  is  currently  analyzing  dmPGE2  and  its 
potential  for  enhancing  engraftment  in  cord  stem  cell 
transplants. In that trial, leukemia or lymphoma patients 
are recruited and treated with high­dose chemotherapy 
before  being  transplanted  with  two  independent  cord 
blood  samples.  One  of  the  cords  is  pretreated  with 
dmPGE2,  and  following  transplantation  the  level  of 
chimerism  is  evaluated  to  determine  which  is  the 
dominant cord. Thus, the trial will investigate whether 
dmPGE2­stimulated  cells  might  display  better  engraft­
ment  capability  over  time,  a  result  that  could  greatly 
increase  the  efficacy  of  cord  blood  and  bone  marrow 
transplantation in humans.
Lessons from the zebrafish model
Through mass mating procedures, the zebrafish can be 
used  in  various  high­throughput  genomic  techniques 
that have not been possible with other vertebrate models. 
The advantages provided by the zebrafish in visualization, 
fate mapping, and early embryonic development contri­
bute greatly to cell biological studies, particularly as they 
pertain to early hematopoietic development and HSCs. 
In addition, mutagenesis, chemical, and other large­scale 
screens are important methods for the discovery of novel 
pathways and potential therapeutics targeting hematopoiesis.
As  mentioned,  transplantation  assays  have  also  been 
developed  in  the  zebrafish  [75,76].  The  first  marrow 
transplants  were  performed  using  GFP­positive  whole 
kidney marrow transplanted into irradiated adults. GFP­
positive  blood  cells  can  be  seen  in  the  host  up  to  6 
months after transplantation. Serial transplantation has 
also  demonstrated  effectiveness,  as  recipients  retain 
GFP­positive  blood  for  months  after  transplant.  More 
recently,  competitive  repopulation  studies  between  red 
and green fluorescently tagged marrow cells have been 
performed in the Casper line, in which marrow cells are 
pretreated with a chemical and evaluated for competitive 
advantage  [60].  Through  the  use  of  this  technology, 
chemicals  can  be  screened  to  assess  their  ability  to 
enhance  transplantation,  and  thus  to  enhance  the 
robustness  of  HSC  development,  engraftment,  and 
retention.
Implications for translational stem cell research
Recent advances in epigenetic and sequencing technolo­
gies, particularly the development of ChIP­seq and RNA­
seq,  have  allowed  the  investigation  of  molecular 
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genome­wide binding sites of the essential hematopoietic 
transcription factors Gata1, Gata2, Runx1, Fli1, and Scl in 
human  megakaryocytes  were  identified  [78].  Analysis 
revealed  144  regions  representing  151  candidate  genes 
that showed simultaneous binding of all five factors. Of 
these genes, 18 had known functions in hematopoiesis, 
and  the  zebrafish  model  was  then  used  to  further 
investigate  these  genes.  Eight  genes  were  chosen  at 
random and targeted for knockdown using morpholinos. 
In each case, morpholino injection caused a significant 
reduction  in  erythrocyte,  thrombocyte,  and/or  HSC 
number. This study demonstrates the effectiveness of the 
zebrafish  model  in  validating  results  found  in  other 
organisms using a high­throughput in vivo system [78].
The use of ChIP­seq analysis has also led to resolution 
of  the  molecular  interplay  among  external  signaling 
transcription factors and cell­specific regulators during 
hematopoietic  regeneration.  In  a  recent  study  using  a 
combination of zebrafish, murine, and human inputs, the 
BMP  and  Wnt  signaling  pathways  were  shown  to  be 
essential for hematopoietic regeneration following acute 
hematopoietic injury [79]. In this study, ChIP­seq analysis 
demonstrated  that  Smad1  and  Tcf7l2  co­occupy  sites 
with cell­specific master regulators in a dynamic manner 
throughout  differentiation.  These  data  suggest  that  the 
hematopoietic program is coordinated by a finely tuned 
collaboration  between  master  regulators  and  external 
signaling factors, in which master regulators direct the 
binding profiles of the signaling transcription factors.
In addition to serving as an effective chemical screening 
platform, the zebrafish model has shown promise as an 
efficient means of prescreening small molecules for drug 
candidacy.  A  recent  study  evaluated  the  specificity  of 
three  molecules  that  are  known  to  inhibit  polo­like 
kinase 1 (Plk1) in vitro, a protein that is overexpressed in 
many  tumors  and  thus  is  considered  a  potentially 
important target for cancer therapy [80]. Analysis of Plk1 
has revealed high conservation between the zebrafish and 
human homologs, including a nearly identical active site 
composition  [81].  The  study  investigated  the  Plk1 
inhibitors  LFM­A13,  ON01910,  and  thiazole­carboxa­
mide  10A  to  determine  which  molecule  provided  the 
most specific and effective inhibition in vivo. The embry­
onic phenotypes resulting from each chemical treatment 
were compared with the phenotype resulting from direct 
morpholino  knockdown  of  Plk1.  The  results  indicated 
that whereas each inhibitor showed promise in vitro, only 
one, thiazole­carboxamide 10A, selectively inhibited Plk1 
in  vivo.  This  result  highlights  the  difficulty  associated 
with the discovery of drug candidates through in vitro 
methods, as well as the significant advantage provided by 
using  the  zebrafish  model  to  prescreen  potential 
therapeutics in vivo [80].
Conclusions and future directions
The  zebrafish  model  provides  a  tremendous  balance 
between scale and applicability. The ease of mutagenesis, 
high fecundity, and visualization techniques, in conjunc­
tion  with  the  largely  conserved  hematopoietic  system 
that  the  zebrafish  provides,  allow  large­scale  genomic 
analysis while maintaining relevance in higher organisms. 
The  definition  of  genes  involved  in  T­ALL  and  hypo­
chromic  anemia,  and  the  discovery  and  assessment  of 
dmPGE2,  thiazole­carboxamide  10A,  and  3F8  have 
demonstrated  the  relevance  of  the  zebrafish  model  for 
clinical and therapeutic research. This model will con­
tinue to help define genetic and epigenetic mechanisms 
in  blood  cells  using  the  high­throughput  procedures 
ChIP­seq, RNA­seq, and morpholino screening. Further 
studies of HSC development, self­renewal, and differen­
tiation using the zebrafish model have great potential to 
contribute to advances in the treatment and management 
of numerous blood diseases and cancers.
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